Before taking Jaypirca(Pirtobrutinib)

Critical safety information for patients and healthcare providers.

Warnings and Precautions

Key precautions include vigilant monitoring for signs and symptoms of infections, bleeding events, and cytopenias. Patients should be assessed for cardiac arrhythmias and monitored for liver toxicity throughout treatment. There is an increased risk of developing second primary malignancies, including skin cancers; sun protection is advised. JAYPIRCA can cause fetal harm, necessitating effective contraception in females of reproductive potential during and for one week after treatment. Breastfeeding is not recommended during therapy.